Obesity, inflammation, and insulin resistance

被引:1338
作者
Shoelson, Steven E.
Herrero, Laura
Naaz, Afia
机构
[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1053/j.gastro.2007.03.059
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Weight gain and obesity are major risk factors for conditions and diseases ranging from insulin resistance and type 2 diabetes mellitus to atherosclerosis and the sequelae of nonalcoholic fatty liver disease. A chronic, subacute state of inflammation often accompanies the accumulation of excess lipid in adipose tissue and liver (hepatic steatosis), evidenced by changes in both inflammatory cells and biochemical markers of inflammation. These changes can be seen in the involved tissues and systemically, in terms of elevated circulating levels of inflammatory markers. The link between obesity and inflammation has therefore raised the important question of whether obesity-induced inflammation plays a pathogenic role in the development and progression of these disorders. We review the rapidly expanding body of animal and clinical data that support potential roles for inflammation in the pathogenesis of insulin resistance and type 2 diabetes mellitus.
引用
收藏
页码:2169 / 2180
页数:12
相关论文
共 137 条
[91]   C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women [J].
Pannacciulli, N ;
Cantatore, FP ;
Minenna, A ;
Bellacicco, M ;
Giorgino, R ;
De Pergola, G .
INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (10) :1416-1420
[92]   No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor:: Fc fusion protein in obese insulin-resistant patients [J].
Paquot, N ;
Castillo, MJ ;
Lefèbvre, PJ ;
Scheen, AJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1316-1319
[93]   A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ [J].
Pascual, G ;
Fong, AL ;
Ogawa, S ;
Gamliel, A ;
Li, AC ;
Perissi, V ;
Rose, DW ;
Willson, TM ;
Rosenfeld, MG ;
Glass, CK .
NATURE, 2005, 437 (7059) :759-763
[94]   Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle [J].
Perreault, M ;
Marette, A .
NATURE MEDICINE, 2001, 7 (10) :1138-1143
[95]   NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X [J].
Pickup, JC ;
Mattock, MB ;
Chusney, GD ;
Burt, D .
DIABETOLOGIA, 1997, 40 (11) :1286-1292
[96]  
Pierce JW, 1996, J IMMUNOL, V156, P3961
[97]   C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus [J].
Pradhan, AD ;
Manson, JE ;
Rifai, N ;
Buring, JE ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (03) :327-334
[98]  
PRIMROSE JN, 1992, THROMB HAEMOSTASIS, V68, P396
[99]  
RADCANELLI V, 2006, HEPATOLOGY, V43, pS54
[100]   ASPIRIN AND DIABETES MELLITUS [J].
REID, J ;
MACDOUGALL, AI ;
ANDREWS, MM .
BRITISH MEDICAL JOURNAL, 1957, 2 (NOV9) :1071-1074